title: Brentuximab Vedotin in CD30+ Lymphomas.
abstract: Monoclonal antibodies (mAb) have become an effective treatment strategy for hematologic malignancies. CD30 is a rational target for therapy due to its limited expression on normal tissues and the strong and uniform expression on malignant cells in classical Hodgkin's lymphoma (cHL) and anaplastic large-cell lymphoma (ALCL). Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, utilizes the targeting properties of mAb to deliver a cytotoxic agent inside the malignant cell. Brentuximab vedotin has significant clinical activity in patients with relapsed or refractory cHL and relapsed or refractory ALCL, and has the potential to represent a significant advance in modern oncology.
authors.affiliation: Hospital Israelita Albert Einstein, Sao Paulo, SP Brazil.
authors.forename: Guilherme Fleury
authors.initials: GF
authors.lastname: Perini
authors.affiliation: Fox Chase Cancer Center, Lymphoma Service, Philadelphia, PA USA.
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
keywords: Anaplastic large-cell lymphoma; Antibody-drug conjugate; Brentuximab vedotin; CD30; Hodgkin’s lymphoma; Monomethylauristatin E; Oncology